臨床泌尿器科69巻12号

2015年11月発行

特集 いまさら聞けない！泌尿器がん化学療法の理論と実践

Ⅳ．疾患別がん化学療法の理論と実践

精巣腫瘍

著者： 安藤正志¹

所属機関： ¹愛知県がんセンター中央病院薬物療法部

ページ範囲：P.1058 - P.1066

文献概要

要旨　精巣腫瘍は化学療法に対する感受性が高く，進行例でも治癒可能例が存在する疾患である。より早く適切な診断を行い，直ちに治療を開始することが重要である。非セミノーマはセミノーマよりも予後不良である。日本泌尿器科学会の臨床病期ⅡB以上を進行例と取り扱い，高位徐睾術後に化学療法を施行し，腫瘍マーカー正常化後に残存腫瘍切除を基本方針とする。シスプラチンを中心とした併用化学療法が行われており，現在のところ標準的レジメンはBEP（ブレオマイシン/エトポシド/シスプラチン）療法である。

参考文献

1）Hanna N and Einhorn LH：Testicular cancer：a reflection on 50 years of discovery. J Clin Oncol 32：3085-3092, 2014

2）Einhorn LH and Donohue J：Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87：293-298, 1977

3）Williams SD, Birch R, Einhorn LH, et al：Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316：1435-1440, 1987

4）International Germ Cell Consensus Classification：a prognostic factor-based staging system for metastatic germ cell cancers：International Germ Cell Cancer Collaborative Group. J Clin Oncol 15：594-603, 1997

5）van Dijk MR, Steyerberg EW and Habbema JD：Survival of non-seminomatous germ cell cancer patients according to the IGCC classification：An update based on meta-analysis. Eur J Cancer 42：820-826, 2006

6）de Wit R, Stoter G, Sleijfer DTh, et al：Four cycles of BEP versus an alternation regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma；a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71：1311-1314, 1995

7）Nichols C, Williams S, Loehrer P, et al：Randomized study of cisplatin dose intensity in poor-risk germ cell tumors：a Southeastern Cancer Study Group and Southwestern Oncology Group protocol. J Clin Oncol 9：1163-1172, 1991

8）de Wit R, Stoter G, Sleijfer DTh, et al：Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma；a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 78：828-832, 1998

9）Nichols CR, Catalano PJ, Crawford ED, et al：Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors：an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16：1287-1293, 1998

10）Kaye SB, Mead GM, Fossa S, et al：Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor：a randomized Medical Research Council/European Organization for Research and Treatment of Cancer Study. J Clin Oncol 16：692-701, 1998

11）Culine S, Kramar A, Theodore C, et al：Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors：Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26：421-427, 2008

12）de Witt R, Skoneczna I, Daugaard G, et al：Randomized phase Ⅲ study comparing paclitaxel-bleomycin, etoposide, and cisplatin（BEP）to standard BEP in intermediate-prognosis germ-cell cancer：Intergroup study EORTC 30983. J Clin Oncol 30：792-799, 2012

13）Droz JP, Kramar A, Biron P, et al：Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours：mature results of a randomised trial. Eur Urol 51：739-746, 2007

14）Motzer RJ, Nichols CJ, Margolin KA, et al：Phase Ⅲ randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25：247-256, 2007

15）Daugaard G, Skoneczna I, Aass N, et al：A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide（VIP）plus stem-cell support in males with poor-prognosis germ-cell cancer：An intergroup study of EORTC, GTCSG, and Grupo Germinal（EORTC30974）. Ann Oncol 22：1054-1061, 2011

16）Bosl GJ, Geller NL, Bajorin D, et al：A randomized trial of etoposide＋cisplatin versus vinblastine＋bleomycin＋cisplatin＋cyclophosphamide＋dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6：1231-1238, 1988

17）Levi J, Raghavan D, Harvey V, et al：The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 11：1300-1305, 1993

18）de Wit R, Stoter G, Kaye S, et al：Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma：a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15：1837-1843, 1997

19）Einhorn LH, Williams SD, Loehrer PJ, et al：Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors：A Southeastern Cancer Study Group protocol. J Clin Oncol 7：387-391, 1989

20）Loehrer P, Johnson D, Elson P, et al：Importance of bleomycin in favorable-prognosis disseminated germ cell tumors：An Eastern Cooperative Oncology Group trial. J Clin Oncol 13：470-476, 1995

21）Culine S, Kerbrat P, Kramar A, et al：Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors：a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers（GETUG T93BP）. Ann Oncol 18：917-924, 2007

22）de Wit R, Roberts T, Wilkinson P, et al：Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer：a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19：1629-1640, 2001

23）Toner G, Stockler M, Boyer, et al：Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors：a randomized trial. Lancet 357：739-745, 2001

24）Grimison PS, Stockler MR, Thomson DB, et al：Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors：updated analysis of a randomized trial. J Natl Cancer Inst 102：1253-1262, 2010

25）Bajorin DF, Sarosdy MF, Pfister DG, et al：Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors：a multi-institutional study. J Clin Oncol 11：598-606, 1993

26）Bokemeyer C, Kohrmann O, Tischler J, et al：A randomized trial of cisplatin, etoposide and bleomycin（PEB）versus carboplatin, etoposide and bleomycin（CEB）for patients with‘good-risk’metastatic non-seminomatous germ cell tumors. Ann Oncol 7：1015-1021, 1996

27）Horwich A, Sleijfer DT, Fossa SD, et al：Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer：a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15：1844-1852, 1997

28）日本泌尿器科学会（編）：精巣腫瘍　診療ガイドライン2015年版．p6，金原出版，東京，2015

29）Sleijfer S：Bleomycin-induced pneumonitis. Chest 120：617-624, 2001

30）O'Sullivan JM, Huddart RA, Norman AR, et al：Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14：91-96, 2003

31）Collette L, Sylvester RJ, Stenning SP, et al：Impact of the treating institution on survival of patients with“poor-prognosis”metastatic nonseminoma. J Natl Cancer Inst 91：839-846, 1999

32）Mazumdar M, Bajorin DF, Bacik J, et al：Predicting outcome to chemotherapy in patients with germ cell tumors：the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19：2534- 2541, 2001

33）Harstrick A, Schmoll HJ, Wilke H, et al：Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9：1549-1555, 1991

34）Pizzocaro G, Salvioni R, Piva L, et al：Modified cisplatin, etoposide（or vinblastine）and ifosfamide salvage therapy for male germ-cell tumors：long-term results. Ann Oncol 3：211-216, 1992

35）Farhat F, Culine S, Theodore C, et al：Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients：the Institut Gustave Roussy experience. Cancer 77：1193-1197, 1996

36）McCaffrey JA, Mazumdar M, Bajorin DF, et al：Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors：response and survival. J Clin Oncol 15：2559-2563, 1997

37）Loehrer PJ, Gonin R, Nichols CR, et al：Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16：2500-2504, 1998

38）International Prognostic Factors Study Group：Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28：4906-4911, 2010

39）Mardiak J, Salek T, Sycova-Mila Z, et al：Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors：a phase Ⅱ study. Neoplasma 52：497-501, 2005

40）Mead GM, Cullen MH, Huddart R, et al：A phase Ⅱ trial of TIP（paclitaxel, ifosfamide and cisplatin）given as second-line（post-BEP）salvage chemotherapy for patients with metastatic germ cell cancer：a medical research council trial. Br J Cancer 93：178-184, 2005

41）Motzer RJ, Sheinfeld J, Mazumdar M, et al：Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18：2413-2418, 2000

42）Kondagunta GV, Bacik J, Donadio A, et al：Combination of paclitacel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23：6549-6555, 2005

43）Pico JL, Rosti G, Kramar A, et al：A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16：1152-1159, 2005

44）Miller JC and Einhorn LH：Phase Ⅱ study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17：36-39, 1990

45）Hinton S, Catalano P, Einhorn LH, et al：Phase Ⅱ study of paclitaxel plus gemcitabine in refractory germ cell tumors（E9897）：a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20：1859-1863, 2002

46）Kollmannsberger C, Beyer J, Liersch R, et al：Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer：a study of the German Testicular Cancer Study Group. J Clin Oncol 22：108-114, 2004